skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Idelalisib (Code C78825)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Idelalisib

Definition: An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.

Display Name: Idelalisib

Label: Idelalisib

NCI Thesaurus Code: C78825 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2698692  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one
GS 1101
Phosphoinositide-3 Kinase Delta Inhibitor CAL-101

External Source Codes: 
CAS Registry Number 870281-82-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 601486
PDQ Open Trial Search ID 601486 (check for NCI PDQ open clinical trial info)
UMLS CUI C2698692

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For relapsed chronic lymphocytic leukemia (CLL)
code C78825
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name PI3K-delta_Inhibitor_CAL-101
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom